- $466.48m
- $431.92m
- $139.88m
- 82
- 32
- 89
- 75
Annual income statement for Innovid, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 56.3 | 68.8 | 90.3 | 127 | 140 |
| Cost of Revenue | |||||
| Gross Profit | 45.8 | 56.4 | 72.5 | 96.9 | 106 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 62.4 | 67.7 | 96.1 | 157 | 173 |
| Operating Profit | -6.04 | 1.12 | -5.85 | -29.7 | -33 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -6.43 | 0.388 | -10.2 | -16.4 | -29.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.33 | -0.812 | -11.5 | -18.4 | -31.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.33 | -0.812 | -11.5 | -18.4 | -31.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.34 | -8.11 | -88.5 | -18.4 | -31.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.079 | -0.067 | -0.704 | -0.107 | -0.145 |
| Dividends per Share |